Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4135152 | 0.78 | CHRM2 (0.43) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL27477105 | 0.78 | PEPD (0.41) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL4135155 | 0.78 | CHRM2 (0.43) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL7318569 | 0.78 | CHRM2 (0.43) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL4135157 | 0.78 | CHRM2 (0.43) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL22447718 | 0.77 | CHRM2 (0.42) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL20569111 | 0.77 | CHRM2 (0.42) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL8175970 | 0.77 | CHRM2 (0.42) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL22508666 | 0.75 | CHRM2 (0.41) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL4614064 | 0.74 | CHRM2 (0.53) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2560976-B9 | FUROPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2017-06-07 | — | — | EP | disclosed |
| EP-2560976-B1 | FUROPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2016-08-24 | — | — | EP | disclosed |
| US-8324239-B2 | Furopyridine compounds and uses thereof | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-20120015907-A1 | Furopyridine compounds and uses thereof | NOVARTIS AG (CH) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015907-A1 | Furopyridine compounds and uses thereof | CYP3A5, QDPR, DPYD | CHRM2 835/4885CHRM4 967/4885CHRM3 708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.